Enhancing protective immune cell subsets represents a potential clinical application for bladder cancer immunotherapy or disease prevention, where strategies could involve boosting CD8+ T cell activity or expanding DN T cell populations. This evidence concerns the gene CD8A and urinary bladder carcinoma.